The activity of temafloxacin hydrochloride was evaluated by agar dilution against 100 clinical isolates of Neisseria gonorrhoeae and compared with the activities of penicillin, tetracycline, ceftriaxone, ciprofloxacin, and ofloxacin. Temafloxacin inhibited 100% of study isolates at a concentration of 0.015 ,Ig/ml or less and was highly active against penicillin-and tetracycline-resistant strains. The in vitro activity of temafloxacin was nearly identical to that of ceftriaxone and was slightly less than that observed with ciprofloxacin and ofloxacin. Temafloxacin represents a promising alternative agent for investigation in the treatment of infection due to N. gonorrhoeae.
Increased resistance to penicillin and tetracycline among Neisseria gonorrhoeae strains has created a demand for alternative therapies (3, 8, 12) . The fluoroquinolones are a useful class of agents for gonococcal infection because of their excellent in vitro activity against N. gonorrhoeae (including penicillin-and tetracycline-resistant strains), good oral bioavailability, and efficacy comparable to that of ceftriaxone in treating uncomplicated gonorrheal disease (2, 5, 11) . Temafloxacin is a difluoroquinolone with a broad spectrum of activity encompassing clinically important aerobic gram-negative and gram-positive pathogens (1, 4, 6, 9, 10) . Preliminary studies have shown temafloxacin to have in vitro activity against N. gonorrhoeae equivalent to those of other fluoroquinolones (1, 6, 9, 10, 13); however, knowledge of the comparative activity of temafloxacin versus standard agents is lacking. We therefore undertook a study comparing the in vitro activity of temafloxacin against N. gonorrhoeae with those of penicillin, tetracycline, ceftriaxone, and two commercially available fluoroquinolones, ciprofloxacin and ofloxacin.
One hundred random clinical isolates of N. gonorrhoeae were obtained from patients attending a sexually transmitted disease clinic in Brooklyn, N.Y. Study isolates were obtained from the following sites: male urethra (48 strains), endocervix (35 strains), rectum (10 strains), and oropharynx (7 strains). Standard laboratory-grade powders were obtained from the manufacturers of each of the study drugs, and appropriate stock solutions were prepared. For temafloxacin, ciprofloxacin, ofloxacin, and ceftriaxone, the dilutions ranged from 0.001 to 4 p,g/ml, and for penicillin and tetracycline, the dilutions ranged from 0.03 to 128 p,g/ml.
Testing of susceptibility to the various antibiotics in vitro was carried out by the agar dilution technique (7) Overall, of the 100 tested isolates, only 15 were susceptible to penicillin (MIC, .0.06 ,ug/ml), an additional 38 were considered moderately susceptible (MIC, 0.12 to 1 ,ug/ml), and 47 were resistant (MIC, 22 ,ug/ml). Resistance to penicillin was determined to be due to penicillinase production in 31 (31%) isolates and chromosomally mediated in 16 (16%). Tetracycline resistance (MIC, .2 ,ug/ml) was encountered with nine of the tested isolates, with high-level tetracycline resistance (MIC, >16 p,g/ml) occurring in eight of nine (88.9%) resistant strains. Two isolates exhibited both penicillinase production and tetracycline resistance, and one isolate showed both chromosomally mediated penicillin resistance and tetracycline resistance. Ceftriaxone was highly active against the N. gonorrhoeae isolates evaluated in this study, including strains showing penicillin and tetracycline resistance. One hundred percent inhibition of growth occurred at a concentration of 0.03 p,g (or less) of ceftriaxone per ml (Table 1) .
Temafloxacin was highly active against the N. gonorrhoeae strains included in this evaluation, with 100% inhibition occurring at a concentration of 0.015 p,g/ml or less; this antibiotic was substantially more active than penicillin and tetracycline and was comparable in activity to ceftriaxone (Table 1 ). In general, there did not seem to be any correlation between penicillin or tetracycline resistance and susceptibility of N. gonorrhoeae to temafloxacin. All 31 penicillinase-producing strains were inhibited by 0.0078 ,ug of temafloxacin per ml, and of the 16 isolates with chromosomally-mediated penicillin resistance, only 6 were found to require an MIC of temafloxacin of >0.0078 p,g/ml.
Temafloxacin's activity against N. gonorrhoeae is compared with those of ciprofloxacin and ofloxacin in Table 1 . Temafloxacin has also demonstrated good in vitro activity against N. gonorrhoeae in a number of previous investigations (1, 4, 6, 9, 10) . Barry and Jones (1) (4) found higher MICgos of 0.125 and 0.25 ,ug/ml, respectively, for temafloxacin versus N. gonorrhoeae. Those reports totaled only 29 clinical isolates, however. In previous studies in which comparisons with other fluoroquinolones were performed, temafloxacin has shown activity similar to those of other agents in its class (1, 6, 9, 10, 13).
Our study, which utilized the largest number of clinical isolates to date and included isolates from the urethra, endocervix, rectum, and oropharynx as well as isolates exhibiting penicillin and/or tetracycline resistance, found temafloxacin to be slightly less active in vitro than ciprofloxacin and ofloxacin. Although differences in activity between these compounds are unlikely to be of clinical importance, clinical confirmation is required. Significantly, we have demonstrated that temafloxacin has in vitro activity against N. gonorrhoeae essentially identical to that of ceftriaxone and superior to those of penicillin and tetracycline. Evaluation of this fluoroquinolone antimicrobial agent in comparative clinical trials appears warranted.
